Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis

• Autoři: WEINBERGEROVÁ Barbora; MAYER Jiří; KABUT Tomas; SPERR Wolfgang R; STEVKOVA Jana; JONASOVA Anna; CERNAN Martin; HERNDLHOFER Susanne; ORAVCOVA Iveta; SRAMEK Jiri; NOVAK Jan; ŠTĚPÁNOVÁ Radka; SZOTKOWSKI Tomas; DRGONA Lubos; ZAK Pavel; VALENT Peter
• Rok publikování: 2024
• Druh: Článek v odborném periodiku
• Časopis / Zdroj: British journal of haematology
• Fakulta / Pracoviště MU: Lékařská fakulta
• www: https://onlinelibrary.wiley.com/doi/10.1111/bjh.19670
• Doi: http://dx.doi.org/10.1111/bjh.19670
• Klíčová slova: acute myeloid leukaemia; antifungal prophylaxis; fungal infection; venetoclax and azacitidine

Přiložené soubory

• Fungal_infection_frequency_in_newly_diagnosed_acute_myeloidleukaemia_patients_treated_with_venetoclax_plus_azacitidine_with_orwithout_antifungal_prophylaxis.pdf

• Popis: Our observational study analysed fungal infection frequency within cohorts with versus without antifungal prophylaxis (AFP) among newly diagnosed first-line venetoclax and azacitidine (VEN + AZA)-treated acute myeloid leukaemias in Czech, Austrian and Slovak haematology centres. Among 186 patients, 85 (46%) received antifungal prophylaxis, while 101 (54%) received no prophylaxis. Fungal infections occurred in 1/85 patients with prophylaxis (1%) and 5/101 patients without prophylaxis (5%) (p = 0.222). No significant difference was recorded between cohorts with and without AFP in terms of death rate (p = 0.296) and overall survival (p = 0.844). In conclusion, most infections were not severe, developing during the first treatment-cycle and did not affect patients' overall outcome.

Související projekty

• Národní ústav pro výzkum rakoviny